The International Myeloma Foundation (IMF) and the EuroFlow consortium introduce a new automated and highly sensitive flow cytometry method for standardized detection of minimal residual disease (MRD) in myeloma patients.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content